Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to L-asparaginase.
Watanabe J, Makita S, Ito Y, Hatta S, Suzuki T, Yuda S, Maeshima AM, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kim SW, Izutsu K. Watanabe J, et al. Among authors: ito y. Ann Hematol. 2018 Sep;97(9):1739-1740. doi: 10.1007/s00277-018-3335-4. Epub 2018 Apr 16. Ann Hematol. 2018. PMID: 29663028 No abstract available.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Development of new agents for peripheral T-cell lymphoma.
Ito Y, Makita S, Tobinai K. Ito Y, et al. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. doi: 10.1080/14712598.2019.1572746. Epub 2019 Jan 29. Expert Opin Biol Ther. 2019. PMID: 30658046 Review.
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Nakai R, Fukuhara S, Maeshima AM, Kim SW, Ito Y, Hatta S, Suzuki T, Yuda S, Makita S, Munakata W, Suzuki T, Maruyama D, Izutsu K. Nakai R, et al. Among authors: ito y. Clin Case Rep. 2019 Nov 15;7(12):2500-2504. doi: 10.1002/ccr3.2543. eCollection 2019 Dec. Clin Case Rep. 2019. PMID: 31893088 Free PMC article.
Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors.
Suzuki T, Fukuhara S, Nomoto J, Yamashita S, Maeshima AM, Ito Y, Hatta S, Yuda S, Makita S, Munakata W, Suzuki T, Maruyama D, Taniguchi H, Ushijima T, Izutsu K, Tobinai K, Kobayashi Y. Suzuki T, et al. Among authors: ito y. Haematologica. 2021 Feb 1;106(2):593-596. doi: 10.3324/haematol.2019.235598. Haematologica. 2021. PMID: 32336683 Free PMC article. No abstract available.
12,213 results
You have reached the last available page of results. Please see the User Guide for more information.